Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library

Molecular Therapy

Volumn 21, Issue 1, 2013, Pages 139-148

  Miura, Yoshiaki ^a   Yamasaki, Satoshi ^a   Davydova, Julia ^a   Brown, Eric ^a   Aoki, Kazunori ^b   Vickers, Selwyn ^a,c   Yamamoto, Masato ^a,c,d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN; ONCOLYTIC ADENOVIRUS;

ADENOVIRUS; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR LIBRARY; MOLECULAR MODEL; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN TARGETING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 84871919798     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.205     Document Type: Article

References (32)

1. Bergelson, JM, Cunningham, JA, Droguett, G, Kurt-Jones, EA, Krithivas, A, Hong, JSet al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses2 and 5. Science 275: 1320-1323. (Pubitemid 27114163)
2. Tomko, RP, Xu, R and Philipson, L (1997). HCAR and MCAR: the human and mousecellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc NatlAcad Sci USA 94: 3352-3356. (Pubitemid 27157315)
3. Waehler, R, Russell, SJ and Curiel, DT (2007). Engineering targeted viral vectors forgene therapy. Nat Rev Genet 8: 573-587. (Pubitemid 47077278)
4. Hallenbeck, PL, Chang, YN, Hay, C, Golightly, D, Stewart, D, Lin, J et al. (1999).A novel tumor-specific replication-restricted adenoviral vector for gene therapy ofhepatocellular carcinoma. Hum Gene Ther 10: 1721-1733. (Pubitemid 29328216)
5. Hecht, JR, Bedford, R, Abbruzzese, JL, Lahoti, S, Reid, TR, Soetikno, RM et al. (2003).A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 withintravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res9: 555-561. (Pubitemid 36182584)
6. Yamamoto, M and Curiel, DT (2010). Current issues and future directions of oncolyticadenoviruses. Mol Ther 18: 243-250.
7. Alemany, R, Balagu? C and Curiel, DT (2000). Replicative adenoviruses for cancertherapy. Nat Biotechnol 18: 723-727.
8. Davydova, J, Le, LP, Gavrikova, T, Wang, M, Krasnykh, V and Yamamoto, M (2004).Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenovirusesfor esophageal adenocarcinoma treatment. Cancer Res 64: 4319-4327. (Pubitemid 38802439)
9. Yamamoto, M, Davydova, J, Wang, M, Siegal, GP, Krasnykh, V, Vickers, SM et al. (2003).Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicativeadenovirus for pancreatic cancer. Gastroenterology 125: 1203-1218. (Pubitemid 37193465)
10. Nicklin, SA, White, SJ, Nicol, CG, Von Seggern, DJ and Baker, AH (2004). In vitro andin vivo characterisation of endothelial cell selective adenoviral vectors. J Gene Med 6:300-308. (Pubitemid 40228047)
11. Joung, I, Harber, G, Gerecke, KM, Carroll, SL, Collawn, JF and Engler, JA (2005).Improved gene delivery into neuroglial cells using a fiber-modified adenovirus vector.Biochem Biophys Res Commun 328: 1182-1187. (Pubitemid 40238758)
12. Nicklin, SA, Von Seggern, DJ, Work, LM, Pek, DC, Dominiczak, AF, Nemerow, GR et al.(2001). Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of theSIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 4: 534-542. (Pubitemid 34026868)
13. Laakkonen, P, Porkka, K, Hoffman, JA and Ruoslahti, E (2002). A tumor-homingpeptide with a targeting specificity related to lymphatic vessels. Nat Med 8: 751-755. (Pubitemid 34778730)
14. Arap, W, Kolonin, MG, Trepel, M, Lahdenranta, J, Card?Vila, M, Giordano, RJ et al.(2002). Steps toward mapping the human vasculature by phage display. Nat Med8: 121-127. (Pubitemid 34155122)
15. Arap, W, Haedicke, W, Bernasconi, M, Kain, R, Rajotte, D, Krajewski, S et al. (2002).Targeting the prostate for destruction through a vascular address. Proc Natl Acad SciUSA 99: 1527-1531. (Pubitemid 34136526)
16. Miura, Y, Yoshida, K, Nishimoto, T, Hatanaka, K, Ohnami, S, Asaka, M et al. (2007).Direct selection of targeted adenovirus vectors by random peptide display on the fiberknob. Gene Ther 14: 1448-1460. (Pubitemid 47500648)
17. Nishimoto, T, Yoshida, K, Miura, Y, Kobayashi, A, Hara, H, Ohnami, S et al. (2009).Oncolytic virus therapy for pancreatic cancer using the adenovirus library displayingrandom peptides on the fiber knob. Gene Ther 16: 669-680.
18. Lupold, SE, Kudrolli, TA, Chowdhury, WH, Wu, P and Rodriguez, R (2007). A novelmethod for generating and screening peptides and libraries displayed on adenovirusfiber. Nucleic Acids Res 35: e138.
19. Hassan, R, Bera, T and Pastan, I (2004). Mesothelin: a new target for immunotherapy.Clin Cancer Res 10(12 Pt 1): 3937-3942. (Pubitemid 38812466)
20. Hassan, R, Laszik, ZG, Lerner, M, Raffeld, M, Postier, R and Brackett, D (2005).Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normalpancreas and chronic pancreatitis. Am J Clin Pathol 124: 838-845. (Pubitemid 41740183)
21. Chang, K and Pastan, I (1996). Molecular cloning of mesothelin, a differentiationantigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl AcadSci USA 93: 136-140. (Pubitemid 26041483)
22. Ramez, PJ, Vickers, SM, Ono, HA, Davydova, J, Takayama, K, Thompson, TC et al.(2008). Optimization of conditionally replicative adenovirus for pancreatic cancer andits evaluation in an orthotopic murine xenograft model. Am J Surg 195: 481-490.
23. Roelvink, PW, Mi Lee, G, Einfeld, DA, Kovesdi, I and Wickham, TJ (1999). Identificationof a conserved receptor-binding site on the fiber proteins of CAR-recognizingadenoviridae. Science 286: 1568-1571.
24. Einfeld, DA, Schroeder, R, Roelvink, PW, Lizonova, A, King, CR, Kovesdi, I et al. (2001).Reducing the native tropism of adenovirus vectors requires removal of both CAR andintegrin interactions. J Virol 75: 11284-11291. (Pubitemid 33063218)
25. Nicklin, SA, Wu, E, Nemerow, GR and Baker, AH (2005). The influence of adenovirusfiber structure and function on vector development for gene therapy. Mol Ther12: 384-393. (Pubitemid 41150124)
26. Reynolds, P, Dmitriev, I and Curiel, D (1999). Insertion of an RGD motif into the HIloop of adenovirus fiber protein alters the distribution of transgene expression of thesystemically administered vector. Gene Ther 6: 1336-1339. (Pubitemid 29359030)
27. Li, M, Bharadwaj, U, Zhang, R, Zhang, S, Mu, H, Fisher, WE et al. (2008). Mesothelinis a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol CancerTher 7: 286-296. (Pubitemid 351302523)
28. Tsuruta, Y, Pereboeva, L, Breidenbach, M, Rein, DT, Wang, M, Alvarez, RD et al.(2008). A fiber-modified mesothelin promoter-based conditionally replicatingadenovirus for treatment of ovarian cancer. Clin Cancer Res 14: 3582-3588.
29. Palmer, D and Ng, P (2003). Improved system for helper-dependent adenoviral vectorproduction. Mol Ther 8: 846-852. (Pubitemid 37527461)
30. Von Seggern, DJ, Kehler, J, Endo, RI and Nemerow, GR (1998). Complementation of afibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type5 fibre protein. J Gen Virol 79 (Pt 6): 1461-1468. (Pubitemid 28258457)
31. Von Seggern, DJ, Huang, S, Fleck, SK, Stevenson, SC and Nemerow, GR (2000).Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transductionof Epstein-Barr virus-transformed B cells. J Virol 74: 354-362. (Pubitemid 30002916)
32. Suzuki, K, Alemany, R, Yamamoto, M and Curiel, DT (2002). The presence of theadenovirus E3 region improves the oncolytic potency of conditionally replicativeadenoviruses. Clin Cancer Res 8: 3348-3359. (Pubitemid 35340708)